InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | 2026-02-10 | Metzger Michael A | Director & Chief Executive Officer | Sale | 17.2K | $21.03 | $361K | 491.7K | View ↗ | |
| 2026-02-09 | 2026-02-10 | Goldan Keith A. | Chief Financial Officer | Sale | 3,410 | $21.03 | $72K | 140.4K | View ↗ | |
| 2026-02-06 | 2026-02-06 | Metzger Michael A | Director & Chief Executive Officer | Sale | 7,412 | $20.62 | $153K | 508.8K | View ↗ | |
| 2026-02-06 | 2026-02-06 | Goldan Keith A. | Chief Financial Officer | Sale | 2,082 | $20.62 | $43K | 143.8K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Revenue | $5.1M-67.9% | $16.0M | $0 | $0-100.0% | $139.7M |
| Cost of product sales | $7.0M+743.8% | $826K | $0 | — | — |
| Research and development expenses | $258.8M+7.1% | $241.6M+48.2% | $163.0M+37.6% | $118.5M+34.3% | $88.2M |
| Selling, general and administrative | $179.7M+48.6% | $120.9M+80.6% | $66.9M+101.2% | $33.3M+31.8% | $25.2M |
| Total operating expenses | $445.4M+22.6% | $363.4M+58.0% | $230.0M+51.5% | $151.8M+33.7% | $113.5M |
| Loss from operations | -$273.1M+19.6% | -$339.7M-47.7% | -$230.0M-51.5% | -$151.8M-678.8% | $26.2M |
| Royalty interest expense | -$33.8M-585.2% | -$4.9M | $0 | — | — |
| Other interest (expense) income | -$6K-700.0% | $1K+100.5% | -$208K+93.4% | -$3.1M | — |
| Interest income | $22.7M-12.9% | $26.1M+23.3% | $21.2M+260.4% | $5.9M+1357.1% | $403K |
| Other expense, net | -$1.3M-419.4% | -$247K+31.6% | -$361K-14.2% | -$316K-256.4% | $202K |
| Total other income | -$12.3M-159.0% | $20.9M+1.6% | $20.6M+751.3% | $2.4M+286.9% | -$1.3M |
| Net income | -$285.4M+10.5% | -$318.8M-52.3% | -$209.4M-40.2% | -$149.3M-699.1% | $24.9M |
| Net loss attributable to common stockholders | -$285.4M+10.5% | -$318.8M-52.3% | -$209.4M-40.2% | -$149.3M-699.1% | $24.9M |
| Basic loss per share attributable to common stockholders | $86.63B+1.2% | $85.62B+21.7% | $70.37B+15.8% | $60.76B+12658521983.3% | $480 |
| Diluted loss per share attributable to common stockholders | $86.63B+1.2% | $85.62B+21.7% | $70.37B+15.8% | $60.76B+13208892508.7% | $460 |
| Net product revenue | |||||
| Collaboration revenue [Member] | |||||
| Milestone revenue | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Announces Participation in Upcoming Investor Conferences
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential